Szela Mary T 4

What Happened
Mary T. Szela, a director of Kura Oncology, was granted 35,000 derivative securities (an option award) on 2026-06-04. The Form 4 reports the grant at $0.00 per share (total reported value $0), indicating an award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-04; instrument reported as derivative (option) at $0.00.
• Shares/options granted: 35,000. Reported total value on Form 4: $0 (derivative).
• Shares/options owned after transaction: Not specified in the provided filing excerpt.
• Footnote: "This option vests in full on the one year anniversary of the date of grant."
• Filing timeliness: Filed on 2026-06-04 (same as transaction date) — appears timely; no 10b5-1 plan or tax-withholding notes listed in the excerpt.

Context
This was an equity award (option grant) to a director — no shares were sold or purchased on the open market. Derivative grants like this are common compensation and do not by themselves indicate buying/selling sentiment. The award vests in full one year after grant, per the footnote.